期刊文献+

复方大黄制剂在糖尿病肾病患者中的应用观察 被引量:2

Application of the Fufang Dahuang preparation in treating diabetic nephropathy
下载PDF
导出
摘要 目的:观察复方大黄制剂在糖尿病肾病患者中的应用效果。方法:选取我院收治的糖尿病肾病患者72例,采取数字随机法分成观察组(n=36)和对照组(n=36)。对照组采取常规治疗,观察组在对照组基础上采取复方大黄制剂治疗,比较两组临床效果。结果:观察组治疗后Cr、UAER水平均低于对照组,差异有统计学意义(P<0.05)。观察组治疗后收缩压水平高于对照组,差异有统计学意义(P<0.05)。观察组治疗后Cr、UAER水平均低于治疗前,差异有统计学意义(P<0.05)。观察组治疗后收缩压水平高于治疗前,差异有统计学意义(P<0.05)。观察组与对照组用药不良反应发生率分别为5.56%、2.78%,两组用药不良反应发生率比较,差异无统计学意义(P>0.05)。结论:复方大黄制剂在糖尿病肾病患者中的应用效果显著,并且用药安全,是有效的治疗方案之一。 Objective: To observe effects of the Fufang Dahuang preparation on diabetic nephropathy. Methods: 72 patients with diabetic nephropathy were randomly divided into the observation group (n=36) and control group (n=36). The control group was treated by routine therapy, and the treatment group took the Fufang Dahuang preparation more. Results:After treatment, the levels of Cr and UAER in the observation group were lower than those in the control group (P<0.05). The level of systolic blood pressure in the observation group was higher than that in the control group (P<0.05). The levels of Cr and UAER in the observation group were lower than those before treatment (P<0.05). The level of systolic blood pressure in the observation group was higher than that before treatment (P<0.05). The incidence of ADRs in the observation group and the control group was 5.56% and 2.78% respectively (P>0.05). Conclusion: The Fufang Dahuang preparation is effective and safe on diabetic nephropathy.
机构地区 济南市中医医院
出处 《中医临床研究》 2016年第32期62-64,共3页 Clinical Journal Of Chinese Medicine
关键词 复方大黄制剂 糖尿病肾病 应用效果 The Fufang Dahuang preparation Diabetic nephropathy Application effects
  • 相关文献

参考文献4

二级参考文献46

  • 1王德琴,施辉.螺内酯与缬沙坦联合治疗对早期糖尿病肾病尿白蛋白排泄率的影响[J].实用医学杂志,2009,25(5):790-791. 被引量:11
  • 2中华医学会糖尿病学分会.中国2型糖尿病防治指南[M].北京:北京大学医学出版社,2013:447-498.
  • 3Forbes JM, Thorpe SR, Thallas-Bonke V. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy [J]. J Am Soc Nephrol, 2005, 16:2363-2372.
  • 4Schjoedt KJ, Andersen S, Rossing P, et al. Aldosterone escape during angiotensin 1I receptor blockade in diabetic nephropathy is associated with enhanced decline in GFR[J]. Diabetologia, 2004,47 : 1936-1939.
  • 5Esteghamati A, Noshad S, Jarrah S, et al. Long- term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial[J]. Nephrol Dial Transplant, 2013, 28: 2823-2833.
  • 6van den Meiraekera AH, Baggen RG, Paulia S, etal. Spironolaetone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function[J]. J Hypertens, 2006, 24:2285- 2292.
  • 7Ziaee A, Abbas Vaezi A, Oveisi S, et al. Effects of additive therapy with spironolactone on albuminuria in diabetes mellitus: A pilot randomized clinical trial [J]. CaspianJ Intern Med, 2013, 4: 648-653.
  • 8董志强.济生肾气丸加黄柏知母治疗糖尿病肾病52例[J].中外健康文摘,2011,8(8):417-418.
  • 9美国NKF-K/D()QIT作组.慢性肾脏病及透析的临床实践指南[M].王海燕,王梅,译.北京:人民卫生出版社,2003:67.
  • 10Joseph A J, Friedman EA. Diabetic nephropathy in the elderly[J]. Clin Geriatr Med, 2009,25 (3) . 373-389.

共引文献22

同被引文献60

引证文献2

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部